Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2017-11-09 Capital/Financing Update
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Redhill Biopharma Ltd. It includes exhibits such as an underwriting agreement and legal opinions, which are typical for announcements related to financing or capital raising activities. The document does not contain financial statements or detailed financial performance data, nor is it an annual or quarterly report. The presence of an underwriting agreement strongly indicates it relates to capital raising. The document length is 2692 characters, which is relatively short and consistent with a filing announcing financing activities rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2017-11-09 English
FORM 424B5
Capital/Financing Update Classification · 100% confidence The document is a Form 424B5 prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, related to a public offering of American Depositary Shares (ADSs) by RedHill Biopharma Ltd. It details the terms of the offering, underwriting discounts, use of proceeds, risk factors, and other offering-related information. This type of filing is a capital raising document describing a securities offering, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering prospectus supplement. Therefore, it fits the category of Capital/Financing Update (CAP).
2017-11-09 English
FORM 6-K
Regulatory Filings Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release announcement about a clinical trial milestone (last patient enrolled in a Phase III study). The document is short (1971 characters) and primarily serves as a regulatory filing to disclose material information to the market. It does not contain financial statements, detailed financial analysis, or comprehensive report content. Form 6-K filings are periodic reports for foreign private issuers to disclose material information and are generally classified under Regulatory Filings (RNS). Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-11-09 English
FORM 6-K
Capital/Financing Update Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release titled 'RedHill Biopharma Prices Public Offering of its American Depositary Shares.' The content focuses on a public offering pricing announcement, which relates to financing activities. The document length is short (1962 characters), and it is not a full financial report but an update on capital raising. Therefore, it fits the category of Capital/Financing Update (CAP).
2017-11-08 English
FORM 424B5
Capital/Financing Update Classification · 95% confidence The document is a Form 424B5, which is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act. It relates to an offering of American Depositary Shares (ADSs) by RedHill Biopharma Ltd. The text includes detailed information about the offering, underwriting, risk factors, use of proceeds, and other offering-related disclosures. This type of document is a capital markets filing that provides updates on fundraising activities and securities offerings. It is not an annual or quarterly report, audit report, earnings release, or any other type of financial or governance report. It is specifically a prospectus supplement related to a securities offering, which falls under the category of Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the actual offering document, not just an announcement or notice. Therefore, the correct classification is CAP with high confidence.
2017-11-07 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about a proposed public offering of American Depositary Shares. The document is a regulatory filing that provides an update on financing activities but does not contain detailed financial statements or comprehensive financial analysis. It is not an earnings release or a full financial report but rather an announcement related to capital raising. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 6008 characters, which is sufficient to contain substantive information, and the content clearly focuses on a financing announcement.
2017-11-07 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.